Bio-Path’s lead drug candidate, prexigebersen (BP1001), is an antisense therapy targeting the Grb2 protein. This protein plays a key role in cancer cell survival and proliferation, making it a ...

God's manifold graces; false teachers; the certainty of Christ's coming. Whereby are given unto us exceeding great and precious promises: that by these ye might be partakers of the divine nature, ...

Suárez-Calvet spent five years in Munich working on TREM2 (Triggering receptor expressed on myeloid cells 2), a protein that ...